Get started
Author

Tomonori Makiguchi

Observed names: Makiguchi, Tomonori, T. Makiguchi, TOMONORI MAKIGUCHI
Institution: Hirosaki University
ORCID: 0000-0001-9249-7904
Observed ORCID: 0000-0001-9249-7904
OpenAlex ID: A5021348192
Serum extracellular vesicular miR-21-5p is a predictor of the prognosis in idiopathic pulmonary fibrosis
2016 · Tomonori Makiguchi, Mitsuhiro Yamada, et al. · Respiratory Research · 130
PDF
The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells
2013 · Mitsuhiro Yamada, Hiroshi Kubo, et al. · Respiratory Research · 112
PDF
Histone deacetylase inhibitor restores surfactant protein-C expression in alveolar-epithelial type II cells and attenuates bleomycin-induced pulmonary fibrosisin vivo
2015 · Chiharu Ota, Mitsuhiro Yamada, et al. · Experimental Lung Research · 46
Increase in circulating ACE-positive endothelial microparticles during acute lung injury
2019 · Yusuke Takei, Mitsuhiro Yamada, et al. · European Respiratory Journal · 38
PDF
Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
2021 · Hisashi Tanaka, Kageaki Taima, et al. · 癌症：英文版 · 16
PDF
Magnitude of influenza virus replication and cell damage is associated with interleukin-6 production in primary cultures of human tracheal epithelium
2014 · Mutsuo Yamaya, Lusamba K. Nadine, et al. · Respiratory Physiology & Neurobiology · 15
Upregulation of leukocyte immunoglobulin-like receptor B4 on interstitial macrophages in COPD; their possible protective role against emphysema formation
2021 · Ayumi Mitsune, Mitsuhiro Yamada, et al. · Respiratory Research · 14
PDF
Diabetic ketoacidosis shortly after COVID ‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD ‐1 and CTLA ‐4 inhibitors: A case report
2022 · Tomonori Makiguchi, Takashi Fukushima, et al. · Thoracic Cancer · 12
A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non–small-cell Lung Cancer
2020 · Hisashi Tanaka, Yukihiro Hasegawa, et al. · Clinical Lung Cancer · 12
Role of G-protein-coupled estrogen receptor in the pathogenesis of chronic asthma
2023 · Masamichi Itoga, Yoshiko Ishioka, et al. · Immunology Letters · 11
Clinical characteristics of Japanese patients with chronic obstructive pulmonary disease (COPD) with comorbid interstitial lung abnormalities: A cross-sectional study
2020 · Manabu Ono, Seiichi Kobayashi, et al. · PLoS ONE · 10
Safety and feasibility of carboplatin and paclitaxel in combination with nintedanib for non-small cell lung cancer patients with idiopathic pulmonary fibrosis: a prospective pilot study
2023 · Tomonori Makiguchi, Hisashi Tanaka, et al. · Translational Lung Cancer Research · 9
PDF
Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
2021 · Tomonori Makiguchi, Hisashi Tanaka, et al. · Thoracic Cancer · 9
PDF
A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A
2024 · A. Mouri, A. Kisohara, et al. · ESMO Open · 8
PDF
Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias
2024 · Mina Ishidoya, Tomonori Makiguchi, et al. · Lung Cancer · 8
Acute Exacerbation of Interstitial Lung Disease After SARS-CoV-2 Vaccination
2022 · Yoshiko Ishioka, Tomonori Makiguchi, et al. · CHEST Journal · 8
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis
2022 · Hisashi Tanaka, Shigeru Tanzawa, et al. · Therapeutic Advances in Medical Oncology · 5
Granulomatosis with Polyangiitis following COVID-19 in an Adolescent
2023 · Yume Nakamura, Fumihiko Okumura, et al. · Internal Medicine · 4
PDF
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01
2024 · Hisashi Tanaka, Tomonori Makiguchi, et al. · European Journal of Cancer · 3
PDF
Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
2023 · Yoshiko Ishioka, Hisashi Tanaka, et al. · Oncology Letters · 3
PDF
The gut microbiota as a potential biomarker in patients with EGFR-mutant lung cancer
2025 · Chiori Tabe, Daisuke Motooka, et al. · Scientific Reports · 2
PDF
[Retracted] Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
2024 · Yoshiko Ishioka, Hisashi Tanaka, et al. · Oncology Letters · 2
PDF
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
2022 · Shigeru Tanzawa, Tomonori Makiguchi, et al. · Therapeutic Advances in Medical Oncology · 2
A case of localized tracheobronchial relapsing polychondritis with positive matrilin-1 staining
2020 · Tomonori Makiguchi, Akira Koarai, et al. · BMC Rheumatology · 2
PDF
Long-term cell storage of RAW 264.7 cells in a deep freezer dampens M2 marker expression
2025 · Tomonori Makiguchi, Akio Nakane, et al. · Journal of Immunological Methods · 1
Works count: 60
Citation count: 489
H-index: 10
I10-index: 11
Year
Topic
Type